Brief Articles
Copyright ©2010 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Diabetes. Nov 15, 2010; 1(5): 153-160
Published online Nov 15, 2010. doi: 10.4239/wjd.v1.i5.153
Efficacy and safety of vildagliptin/pioglitazone combination therapy in Korean patients with diabetes
Sun-Woo Kim, Sei Hyun Baik, Kun Ho Yoon, Hyoung Woo Lee, Claudia Filozof
Sun-Woo Kim, Kangbuk Samsung Hospital, Seoul 110-746, South Korea
Sei Hyun Baik, Korea University Guro Hospital, Seoul 152-703, South Korea
Kun Ho Yoon, Catholic University Medical Center, Kangnam St. Mary’s Hospital, Seoul 137-701, South Korea
Hyoung Woo Lee, YeungNam University Medical Center, Daegu 705-030, South Korea
Claudia Filozof, Novartis Pharma AG, Postfach, Basel, CH-4002 Switzerland
Author contributions: Kim SW, Baik SH, Yoon KH, and Lee HW have authored this paper on behalf of the following study investigators: Moon Kyu Lee, Bong Soo Cha, Jeong Taek Woo, In Ju Kim, Jeong Hyun Park, Dong Seop Choi, Sung Woo Park, Kyung Soo Ko, In Kyu Lee, Tae Sun Park, and Hak Chul Jang; and Filozof C has authored this paper on behalf of many individuals at Novartis who have contributed to the design, implementation, analysis and reporting of the data, including Jia Y, Amiour Y, Couturier A and Kothny W.
Supported by the Novartis Pharmaceuticals Corporation
Correspondence to: Claudia Filozof, MD, PhD, Principal Medical Scientific Expert, Novartis Pharma AG, Postfach, Basel, CH-4002, Switzerland. claudia.filozof@novartis.com
Telephone: +41-61-3242987 Fax: +41-61-3247921
Received: March 6, 2010
Revised: August 30, 2010
Accepted: September 6, 2010
Published online: November 15, 2010
Core Tip